I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Sep 16 / Springer Healthcare

Genomic modifiers in Huntington’s disease

Description

Galen Wright talks about the latest status of genomic modifiers for Huntington’s disease, why they are key to clinical prediction, and their potential as alternative therapeutic targets to huntingtin-lowering strategies.

Sign up or login to unlock the full suite of MEDICALLY features

Related Content

Sign up or login to unlock the full suite of MEDICALLY features

Sep 18 / Roche
A Phase II dose-finding study of tominersen
Exploratory post hoc analyses from the Phase III GENERATION HD1 study (NCT03761849) suggested that lower exposure tominersen may have potential benefit in younger adults with less disease burden. This presentation outlines the rationale and study design of a new Phase II study of tominersen.

Sign up or login to unlock the full suite of MEDICALLY features

Independent content
Sep 18 / Springer Healthcare
Advanced therapies: Overcoming the challenges
Anne Rosser reflects on the challenges of developing and delivering advanced therapies for Huntington’s disease and highlights what is being done to overcome them to realize future research possibilities.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 17 / Roche
Towards an understanding of the post-treatment and mechanistic aspects of tominersen
GENERATION HD1 (NCT03761849) was a randomised, multicentre, double-blind, Phase III, placebo-controlled trial designed to evaluate the safety and efficacy of tominersen in adults with manifest Huntington’s disease. In March 2021, dosing was stopped in GENERATION HD1 following a recommendation from the independent data monitoring committee. This presentation outlines data from the GENERATION HD1 post-treatment analysis which further our mechanistic understanding of tominersen and support next steps for the tominersen programme.